Browsing Tag
VYKAT XR
2 posts
Prader-Willi syndrome: What families need to know about causes, care, and the treatment breakthrough that just changed everything
Prader-Willi syndrome explained for families and carers: causes, diagnosis, care, the 2025 FDA approval of Vykat XR, and what the latest trials mean for treatment.
Could Neurocrine’s $2.9bn Soleno deal turn VYKAT XR into its next rare-disease blockbuster?
Neurocrine is buying Soleno for $2.9 billion to add VYKAT XR. Read what the deal means for NBIX growth, rare-disease strategy, and investor sentiment.